View Filing Data

Print Document View Excel Document

Document And Entity Information - shares shares in Thousands	6 Months Ended
	Jun. 30, 2017	Aug. 14, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q2
Entity Registrant Name	FENNEC PHARMACEUTICALS INC.
Entity Central Index Key	0001211583
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	FENCF
Entity Common Stock, Shares Outstanding		15,630,663

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 10,232	$ 3,926
Prepaid expenses	21	43
Other current assets	6	3
Total assets	10,259	3,972
Current liabilities:
Accounts payable	296	244
Accrued liabilities	94	125
Derivative instruments (Note 4)	190	33
Total current liabilities	580	402
Total liabilities	580	402
Commitments and contingencies (Note 8)
Stockholders' equity:
Common stock, no par value; unlimited shares authorized; 15,629 shares issued and outstanding (2016-13,643)	82,277	74,515
Additional paid-in capital	42,885	42,134
Accumulated deficit	(116,726)	(114,322)
Accumulated other comprehensive income	1,243	1,243
Total stockholders’ equity	9,679	3,570
Total liabilities and stockholders’ equity	$ 10,259	$ 3,972

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Thousands	Jun. 30, 2017	Dec. 31, 2016
Common stock, no par value	$ 0	$ 0
Common stock, shares issued	15,629	13,643
Common stock, shares outstanding	15,629	13,643

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenue	$ 0	$ 0	$ 0	$ 0
Operating expenses:
Research and development	333	139	558	186
General and administrative	1,146	568	1,692	975
Loss from operations	(1,479)	(707)	(2,250)	(1,161)
Other (expense) income :
Unrealized (loss)/gain on derivatives (Note 4)	(120)	(17)	(157)	26
Other loss	(4)	(3)	(5)	(12)
Interest income and other	5	3	8	3
Total other (expense)/income, net	(119)	(17)	(154)	17
Net loss	$ (1,598)	$ (724)	$ (2,404)	$ (1,144)
Basic net loss per common share	$ (0.11)	$ (0.06)	$ (0.17)	$ (0.10)
Diluted net loss per common share	$ (0.11)	$ (0.06)	$ (0.17)	$ (0.10)
Weighted-average number of common shares outstanding, basic	14,192	12,813	13,917	11,873
Weighted-average number of common shares outstanding, diluted	14,192	12,813	13,917	11,873

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Operating activities:
Net loss	$ (1,598)	$ (724)	$ (2,404)	$ (1,144)
Adjustments to reconcile net loss to net cash used in operating activities:
Unrealized loss/(gain) on derivative	120	17	157	(26)
Stock-based compensation - contractors	286	17	342	30
Stock-based compensation - employees	461	111	502	111
Changes in operating assets and liabilities:
Prepaid assets	11	22	22	58
Other current assets	(1)	(2)	(3)	(4)
Accounts payable	71	120	52	48
Accrued liabilities	(38)	(31)	(31)	(42)
Net cash used in operating activities	(688)	(470)	(1,363)	(969)
Financing activities:
Issuance of units, options and warrants exercised	98	6	98	108
Private placement	7,571	5,000	7,571	5,000
Net cash provided by financing activities	7,669	5,006	7,669	5,108
Increase in cash and cash equivalents	6,981	4,536	6,306	4,139
Cash and cash equivalents - Beginning of period	3,251	545	3,926	942
Cash and cash equivalents - End of period	$ 10,232	$ 5,081	$ 10,232	$ 5,081

Condensed Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income
Balance at Dec. 31, 2016	$ 3,570	$ 74,515	$ 42,134	$ (114,322)	$ 1,243
Balance (in shares) at Dec. 31, 2016		13,643
Stock options issued \| Contractors [Member]	56	$ 0	56	0	0
Stock options issued \| Employees [Member]	41	0	41	0	0
Net loss	(806)	0	0	(806)	0
Balance at Mar. 31, 2017	2,861	$ 74,515	42,231	(115,128)	1,243
Balance (in shares) at Mar. 31, 2017		13,643
Balance at Dec. 31, 2016	$ 3,570	$ 74,515	42,134	(114,322)	1,243
Balance (in shares) at Dec. 31, 2016		13,643
Exercise of stock options (in shares)	36
Net loss	$ (2,404)
Balance at Jun. 30, 2017	9,679	$ 82,277	42,885	(116,726)	1,243
Balance (in shares) at Jun. 30, 2017		15,629
Balance at Mar. 31, 2017	2,861	$ 74,515	42,231	(115,128)	1,243
Balance (in shares) at Mar. 31, 2017		13,643
Stock options issued \| Contractors [Member]	286	$ 0	286	0	0
Stock options issued \| Employees [Member]	461	0	461	0	0
Exercise of stock options	98	$ 191	(93)	0	0
Exercise of stock options (in shares)		86
Rights offering	7,571	$ 7,571	0	0	0
Rights offering (in shares)		1,900
Net loss	(1,598)	$ 0	0	(1,598)	0
Balance at Jun. 30, 2017	$ 9,679	$ 82,277	$ 42,885	$ (116,726)	$ 1,243
Balance (in shares) at Jun. 30, 2017		15,629

Nature of Business and Going Concern

6 Months Ended

Jun. 30, 2017

Going Concern [Abstract]

Nature of Business and Going Concern

1.	Nature of Business and Going Concern

Fennec Pharmaceuticals Inc. (“Fennec”) was originally formed as a British Columbia corporation under the name Adherex Technologies Inc. and subsequently changed its name on September 3, 2014. Fennec, together with its wholly owned subsidiaries Oxiquant, Inc. (“Oxiquant”) and Fennec Pharmaceuticals, Inc., both Delaware corporations, and Cadherin Biomedical Inc. (“CBI”), a Canadian corporation, collectively referred to herein as the “Company,” is a biopharmaceutical company focused on the development of Sodium Thiosulfate (“STS”) for the prevention of ototoxicity from cisplatin in pediatric patients. With the exception of Fennec Pharmaceuticals, Inc., all subsidiaries are inactive.

These unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) that are applicable to a going concern which contemplates that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business.

During the six months ended June 30, 2017, the Company incurred a loss from operations of $2,250. At June 30, 2017, it had an accumulated deficit of $116,726 and had experienced negative cash flows from operating activities during the six months ended June 30, 2017 in the amount of $1,363.

These circumstances raise substantial doubt as to the ability of the Company to meet its obligations as they come due and, accordingly, the use of accounting principles applicable to a going concern may not be appropriate. The Company will need to obtain additional funding in the future in order to finance the Company’s business strategy, operations and growth through the issuance of equity, debt or business combinations. If the Company fails to arrange for sufficient capital on a timely basis, the Company may be required to curtail its business activities until it can obtain adequate financing. However, as of June 30, 2017, we had cash, cash equivalents of $10,232 and believe that our cash resources will be sufficient to meet our cash requirements through and beyond current fiscal year.

These financial statements do not reflect the potentially material adjustments in the carrying values of assets and liabilities, the reported expenses, and the balance sheet classifications used, that would be necessary if the going concern assumption were not appropriate.

Significant Accounting Policies

6 Months Ended

Jun. 30, 2017

Significant Accounting Policies [Abstract]

Significant Accounting Policies

Significant Accounting Policies

Basis of presentation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with US GAAP and are the responsibility of the Company’s management. These unaudited interim condensed consolidated financial statements do not include all of the information and notes required by US GAAP for annual financial statements. Accordingly, these unaudited interim condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements and notes filed with the Securities and Exchange Commission (“SEC”) in the Company's Annual Report on Form 10-K for the year ended December 31, 2016. The Company's accounting policies are consistent with those presented in the audited consolidated financial statements included in the Annual Report on Form 10-K for the year ended December 31, 2016. These unaudited interim condensed consolidated financial statements have been prepared in U.S. dollars. All amounts presented are in thousands except for per share amounts.

Use of estimates

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the interim condensed consolidated financial statements and the reported amounts of expense during the reporting period. Actual results could differ from those estimates.

In the opinion of management, these unaudited interim condensed consolidated financial statements include all adjustments, which are normal and recurring in nature, necessary for the fair presentation of the Company’s financial position at June 30, 2017 and to state fairly the results for the periods presented. The most significant estimates utilized during the quarter ended June 30, 2017 included estimates necessary to value derivative instruments, disclosed in Note 4.

New accounting pronouncements

In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. ASU 2017-01 requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of identifiable assets, the set of assets would not represent a business. Also, in order to be considered a business, an acquisition would have to include an input and a substantive process that together significantly contribute to the ability to produce outputs. Under the update, fewer sets of assets are expected to be considered businesses. ASU 2017-01 is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. The adoption of this guidance is not expected to have a significant effect on the Company's consolidated financial position, results of operations, or cash flows.

In February 2017, the FASB issued ASU No. 2017-05, “Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610-20): Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets” (“ASU 2017-05”). ASU 2017-05 is meant to clarify the scope of the original guidance within Subtopic 610-20 that was issued in connection with ASU 2014-09, as defined below, which provides guidance for recognizing gains and losses from the transfer of nonfinancial assets in contracts with noncustomers. ASU 2017-05 also added guidance for partial sales of nonfinancial assets. ASU 2017-05 is effective for our fiscal year beginning December 31, 2018 and we are required to adopt ASU 2017-05 concurrent with the adoption of ASU 2014-09. We are currently evaluating the impact that the adoption of ASU 2017-05 may have on our consolidated financial statements and disclosures.

In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting (“ASU 2017-09”). The FASB issued ASU 2017-09 to clarify and reduce both (i) diversity in practice and (ii) cost and complexity when applying the guidance in Topic 718, to a change to the terms and conditions of a share-based payment award. This guidance is effective for the Company as of the fourth quarter of its fiscal year ending December 31, 2018. Early adoption is permitted. The amendments in this ASU should be applied prospectively to an award modified on or after the adoption date. The Company is currently evaluating the impact of this updated standard, but does not believe this update will have a significant impact on its consolidated financial statements.

In May 2014, the FASB issued ASU 2014-9, Revenue from Contracts with Customers (Topic 606), to clarify the principles for recognizing revenue. This update provides a comprehensive new revenue recognition model that requires revenue to be recognized in a manner to depict the transfer of goods or services to a customer at an amount that reflects the consideration expected to be received in exchange for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients related to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. These standards have the same effective date and transition date of January 1, 2018. The new revenue standard allows for either full retrospective or modified retrospective application. The Company currently does not have any revenue. It is therefore evaluating the effect of this ASU will have on its statement and disclosures in connection with its prospective revenue stream.

In February 2016, the FASB issued ASU 2016-02, Leases, which amends the accounting guidance related to leases. These changes, which are designed to increase transparency and comparability among organizations for both lessees and lessors, include, among other things, requiring recognition of lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. Adoption and implementation of the guidance is not required by the Company until the beginning of fiscal 2020, although early adoption is permitted. The Company has not yet completed its assessment of the impact that adoption of this guidance will have on its financial statements.

In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting, which amends the accounting for share-based payment transactions. These changes, which are designed for simplification, involve several aspects of the accounting for share-based transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Adoption and implementation of the guidance is not required by the Company until the beginning of fiscal 2018, although early adoption is permitted. The Company has not yet completed its assessment of the impact that adoption of this guidance will have on its financial statements

Cash and cash equivalents

Cash equivalents consist of highly liquid investments with original maturities at the date of purchase of three months or less. The Company places its cash and cash equivalents in investments held by highly rated financial institutions in accordance with its investment policy designed to protect the principal investment. At June 30, 2017, the Company had $10,232 in cash and money market accounts ($3,926 at December 31, 2016). At June 30, 2017, the Company held $127 in cash of which $67 (as presented in US dollars) was in Canadian dollars ($51 at December 31, 2016 as presented in US dollars). At June 30, 2017, the Company held $10,105 in money market investments. Money market investments typically have minimal risks. The Company has not experienced any loss or write-down of its money market investments since inception.

Earnings per Share

6 Months Ended

Jun. 30, 2017

Earnings Per Share [Abstract]

Earnings Per Share

Earnings per Share

Earnings per common share is presented under two formats: basic earnings per common share and diluted earnings per common share. Basic earnings per common share is computed by dividing net income attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per common share is computed by dividing net income by the weighted average number of common shares outstanding during the period, plus the potentially dilutive impact of common stock equivalents (i.e. stock options and warrants). Dilutive common share equivalents consist of the incremental common shares issuable upon exercise of stock options and warrants. The following table sets forth the computation of basic and diluted net loss per share:

	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Numerator:
Net (loss)	$	(1,598)	$	(724)	$	(2,404)	$	(1,144)

Denominator:
Weighted-average common shares, basic		14,192		12,813		13,917		11,873

Dilutive effect of stock options		-		-		-		-
Dilutive effect of warrants		-		-		-		-
Incremental dilutive shares		-		-		-		-

Weighted-average common shares, dilutive		14,192		12,813		13,917		11,873

Net (loss) per share, basic and diluted	$	(0.11)	$	(0.06)	$	(0.17)	$	(0.10)

The following outstanding options and warrants were excluded from the computation of basic and diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:

	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Options to purchase common stock		2,641		2,137		2,641		2,137
Warrants to purchase common stock		1,383		1,749		1,383		1,749

Derivative Instruments

6 Months Ended

Jun. 30, 2017

Derivative Instruments [Abstract]

Derivative Liabilities

Derivative Instruments

The Company's outstanding warrants denominated in Canadian dollars are not considered to be indexed to its own stock because the exercise price is denominated in Canadian dollars and the Company's functional currency is United States dollars. Therefore, these warrants have been treated as derivative financial instruments and recorded at their fair value as a liability. All other outstanding convertible instruments are considered to be indexed to the Company's stock, because their exercise price is denominated in the same currency as the Company's functional currency, and are included in stockholders' equity.

The Company's derivative instruments include options to purchase 39 common shares, the exercise prices for which are denominated in a currency other than the Company's functional currency, as follows:

Contractor options to purchase 20 common shares exercisable at CAD$1.89 per whole common share that expire on November 19, 2017;

Contractor options to purchase 17 common shares exercisable at CAD$1.62 per whole common share that expire on April 4, 2018;

Contractor options to purchase 2 common shares exercisable at CAD$2.43 per whole common share that expire on May 18, 2018.

These options have been recorded at their fair value as a liability at issuance and will continue to be re-measured at fair value as a liability at each subsequent balance sheet date. Any change in value between reporting periods will be recorded as unrealized gain/(loss). These options will continue to be reported as a liability until such time as they are exercised, forfeited or expire. The fair value of these warrants and options is estimated using the Black-Scholes option-pricing model using the following assumptions for the current balance sheet date: expected dividend 0%; risk-free interest rate 1.10%; expected volatility between 88% - 98%; and an expected life between 0.5 – 0.88 years.

Comparative data related to gain/(loss) recorded on re-measurement of the derivative liability for the three and six-month period ended June 30, 2017 and 2016 are summarized in the table below. There is no cash flow impact for these derivatives until the warrants and/or options are exercised. If these warrants or options are exercised, the Company will receive the proceeds from the exercise at the current exchange rate at the time of exercise.

During the fiscal years ended December 31, 2011 and 2010, the Company issued 36 and 29, respectively, options to contractors with a Canadian dollar denominated strike price. Consequently, the Company now has derivatives relating to these options since the strike price is denominated in a currency other than the US dollar functional currency of the Company. While there is an exception to this rule for employees in ASU 2010-13 "Compensation-Stock Compensation (Topic 718): Effect of denominating the exercise price of a share based payment award in the currency of the market in which the underlying equity security trades", no such exception exists for contractors. These options will be marked to market until the earlier of their expiry, exercise or forfeiture.

	Three Months Ended June 30,				Six Months Ended June 30,
Gain/(Loss) on Derivative Instruments	2017		2016		2017		2016
Derivatives expired March 29, 2016		-		-		-		41
Options to contractors		(120)		(17)		(157)		(15)
Gain/(loss) on Derivative Instruments		(120)		(17)		(157)		26

The table below summarizes Canadian dollar denominated contractor option activity, since their issuance:

Contractor Options in $CAD	Three Month Period		Six-Month Period		Weighted-Average
Options in Thousands	Ending June 30, 2017				Exercise Price
Opening balance		40		40	$	1.81
Exercised		(1)		(1)	$	1.89
Forfeited		-		-	$	-
Expired		-		-	$	-
Ending balance		39		39	$	1.80

Canadian dollar denominated options issued to contractors vest immediately and are treated as derivative liabilities. In the case a derivative option is exercised, upon the exercise date, the Company extinguishes the derivative liability, records the cash received and the shares issued into common stock and additional paid in capital accordingly. During the three and six-month period ended June 30, 2017, there was an exercise of 1 Canadian denominated option being treated as a derivative liability. This exercise resulted in $1 gross proceeds to the Company.

Shareholder rights plan

6 Months Ended

Jun. 30, 2017

Shareholder rights plan [Abstract]

Shareholder rights plan

Shareholder rights plan

On June 27, 2017, the Company’s shareholders approved a Shareholder Rights Plan Agreement (the "Rights Plan") for the Company. The Rights Plan is to ensure, to the extent possible, that all shareholders of the Corporation are treated fairly and equally in connection with any take-over bid or other acquisition of control of the Corporation. The Rights Plan is designed to require any potential transaction that will result in a person owning, in the aggregate, 20% or more of the outstanding Common Shares to be structured as a formal take-over bid that satisfies certain minimum requirements relating primarily to the manner in which the bid must be made, the minimum number of days the bid must remain open, and the minimum number of shares that must be acquired under the bid.

Stockholders' Equity

6 Months Ended

Jun. 30, 2017

Stockholders' Equity [Abstract]

Stockholders' Equity

Stockholders' Equity

Authorized capital stock

The Company’s authorized capital stock consists of an unlimited number of shares of no par common stock.

Equity financing

During the three months ended June 30, 2017, the Company completed the closing of a non-brokered private placement of 1,900 common shares for gross proceeds of $7,600 ($7,571 net issuance costs) to various investors. Each common share was issued at a price of USD$4.00.

Warrants to Purchase Common Stock

The Company has warrants outstanding to purchase common stock priced in U.S. dollars with a weighted average price of $1.55 and a weighted average remaining life of 1.65 years. During the six-months ended June 30, 2017, there have been no changes in the amount of warrants outstanding for the Company.

Warrant	Common Shares Issuable Upon Exercise of		Exercise Price
Description	Outstanding Warrants at June 30, 2017		$USD			Expiration Date
Investor warrants		1,333	$	1.50	USD	November 22, 2018
Investor warrants		50	$	3.00	USD	February 2, 2019
Total		1,383

Stock option plan

The Compensation Committee of the Board of Directors administers the Company’s stock option plan. The Compensation Committee designates eligible participants to be included under the plan and approves the number of options to be granted from time to time under the plan. Currently, the maximum number of option shares issuable is twenty-five percent (25%) of the total number of issued and outstanding shares of common stock. Based upon the current shares outstanding, a maximum of 3,907 options are authorized for issuance under the plan. For all options issued under the plan, the exercise price is the fair value of the underlying shares on the date of grant. All options vest within three years or less and are exercisable for a period of seven years from the date of grant. The stock option plan allows the issuance of Canadian and U.S. dollar grants. The table below outlines recognized contractor and employee expense for the three and six-month periods ended June 30, 2017 and 2016.

	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Contractor options expense recognized		286		17		342		30
Employee options expense recognized		461		111		502		111
Total option expense recognized		747		128		844		141

Stock option activity

The following is a summary of option activity for the three and six months ended June 30, 2017 for stock options denominated in US dollars:

	Number of		Weighted-Average
US Denominated Options	Options (thousands)		Exercise Price $USD
Outstanding December 31, 2016		1,428		1.93
Granted		-		-
Exercised		-		-
Forfeited		-		-
Outstanding at March 31, 2017		1,428		1.93
Granted		300		4.84
Exercised		(50)		0.64
Forfeited		-		-
Outstanding at June 30, 2017		1,678		2.48

During the three months ended June 30, 2017, US denominated option exercises provided gross proceeds of $32 and resulted in the issuance of 50 Common shares. Of the 1,678 options granted and outstanding at June 30, 2017, 1,378 are fully vested and 1,228 are exercisable.

The following is a summary of option activity for the three and six months ended June 30, 2017 for stock options denominated in Canadian dollars:

	Number of		Weighted-Average
Canadian Denominated Options	Options (thousands)		Exercise Price $CAD
Outstanding December 31, 2016		999		2.38
Granted		-		-
Exercised		-		-
Forfeited		-		-
Outstanding at March 31, 2017		999		2.38
Granted		-		-
Exercised		(36)		2.42
Forfeited		-		-
Outstanding at June 30, 2017		963		2.37

For the three and six months ended June 30, 2017, there was no activity related to Canadian dollar denominated options issued. There were exercises of 36 Canadian denominated options (1 treated as a derivative, 35 as non-derivative). These exercises resulted in gross proceeds of CAD$87 ($66 as presented in US dollars). During the same three and six-month periods ended in 2016, there was no activity related to Canadian dollar denominated options. As of June 30, 2017, all outstanding options denominated in Canadian dollars were fully vested.

Valuation assumptions

The value of options granted were estimated using the Black-Scholes option pricing model using the following assumptions in the table below: The expected volatility was determined using historical volatility of our stock based on the contractual life of the award. There were 300 options issued during the three months ended June 30, 2017, (49 for the same period in 2016). There were no issuances of options during quarters ended March 31, 2017 and 2016. Assumptions for the valuation of the option grants are described in the table below:

	Three Months Ended June 30,
Black-Scholes Model Assumptions	2017			2016
Expected dividend		0.00	%		0.00	%
Risk free rate		2.04 – 2.16	%		1.51	%
Expected volatility		133 - 167	%		137	%
Expected life		7 years			7 years

Fair Value Measurements

6 Months Ended

Jun. 30, 2017

Fair Value Disclosures [Abstract]

Fair Value Measurements

Fair Value Measurements

The Company adopted the Fair Value Measurements and Disclosure Topic of the FASB in 2011. This Topic applies to certain assets and liabilities that are being measured and reported on a fair value basis. The Topic defines fair value, establishes a framework for measuring fair value in accordance with US GAAP, and expands disclosure about fair value measurements. This Topic enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The Topic requires that financial assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

Fair Value Measurement at June 30, 2017

Quoted Price in

Active Markets for

Significant

Assets/Liabilities Measured at

Identical

Significant Other

Unobservable

Fair Value on a Recurring Basis

Instruments

Observable Inputs

Inputs

Level 1

Level 2

Level 3

Total

Assets

Cash and cash equivalents

127

⁽¹⁾

10,105

10,232

Liabilities

Derivative liabilities

190

(1)

The Company held $127 in cash of which $67 (as presented in US dollars) was in Canadian funds.

The Company's financial instruments include cash and cash equivalents and derivatives. The derivative liabilities include options issued to contractors in a currency other than the functional currency of the Company.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Commitments and Contingencies

6 Months Ended

Jun. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and contingencies

Commitments and contingencies

Oregon Health & Science University Agreement

On February 20, 2013, Fennec entered into a new exclusive license agreement with Oregon Health & Science University (“OHSU”) for exclusive worldwide license rights to intellectual property directed to STS and its use for chemoprotection, including the prevention of ototoxicity induced by platinum chemotherapy, in humans (the "New OHSU Agreement").

The term of the New OHSU Agreement expires on the date of the last to expire claim(s) covered in the patents licensed to the Company, unless earlier terminated as provided in the agreement. STS is currently protected by methods of use patents that the Company exclusively licensed from OHSU that expire in Europe, Canada and Australia in 2021 and are currently pending in the United States and Japan. The New OHSU Agreement is terminable by either Fennec or OHSU in the event of a material breach of the agreement by either party after 45 days prior written notice. Fennec has the right to terminate the New OHSU Agreement at any time upon 60 days prior written notice and payment of all fees due to OHSU under the New OHSU Agreement.

On May 18, 2015, Fennec negotiated an amendment ("Amendment 1") to the exclusive license agreement with OHSU. Amendment 1 expands the exclusive license agreement signed with OHSU on February 20, 2013 or New OHSU Agreement to include the use of N-acetylcysteine as a standalone therapy and/or in combination with Sodium Thiosulfate ("STS") for the prevention of ototoxicity induced by chemotherapeutic agents to treat cancers. Further, Amendment 1 adjusts select milestone payments entered in the OHSU Agreement including but not limited to the royalty rate on net sales for licensed products, royalty rate from sublicensing of the licensed technology and the fee payable upon the regulatory approval of a licensed product. The term of Amendment 1 under the OHSU Agreement expires on the date of the last to expire claim(s) covered in the patents licensed to Fennec or 8 years, whichever is later. In the event a licensed product obtains regulatory approval and is covered by the Orphan Drug Designation, the parties will in good faith amend the term of the agreement.

Executive Severance

In the event of his termination with us other than for cause, the Company will pay its Chief Executive Officer, Rostislav Raykov, a one-time severance compensation payment equal to 12 months of salary (currently $250). Further, the Company will pay Chief Financial Officer, Robert Andrade, a one-time severance compensation equal to six-months salary (currently $95).

Leases

The Company has an operating lease in Research Triangle Park, North Carolina. This operating lease is terminable with 30 days’ notice and has no penalties or contingent payments due. The Company had rent expense of $1 during the quarter ended June 30, 2017 and $3 for the six-months ended June 30, 2017.

Subsequent events

6 Months Ended

Jun. 30, 2017

Subsequent Events [Abstract]

Subsequent Events

Subsequent events

Registration of Certain Common Shares and Warrants

On August 11, 2017, the Company filed a Form S-1 with the Securities and Exchange Commission to register the 8,243 common shares, which includes 1,383 common shares issuable upon exercise of warrants. The S-1 filing covers shareholders of common shares and warrants from the following transactions:

⋅

The Company’s April 2010 private placement of common shares and warrants to purchase common shares;

⋅

The Company’s November 2013 private placement of common shares and warrants to purchase common shares;

⋅

The Company’s February 2016 private placements of warrants to purchase common shares in lieu of payment for services rendered;

⋅

The Company’s May 2016 private placement of common shares; and

⋅

The Company’s June 2017 private placement of common shares.

Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2017

Significant Accounting Policies [Abstract]

Basis of presentation

Basis of presentation

Use of estimates

Use of estimates

New accounting pronouncements

New accounting pronouncements

Cash and cash equivalents

Cash and cash equivalents

Earnings per Share (Tables)

6 Months Ended

Jun. 30, 2017

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

The following table sets forth the computation of basic and diluted net loss per share:

	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Numerator:
Net (loss)	$	(1,598)	$	(724)	$	(2,404)	$	(1,144)

Denominator:
Weighted-average common shares, basic		14,192		12,813		13,917		11,873

Dilutive effect of stock options		-		-		-		-
Dilutive effect of warrants		-		-		-		-
Incremental dilutive shares		-		-		-		-

Weighted-average common shares, dilutive		14,192		12,813		13,917		11,873

Net (loss) per share, basic and diluted	$	(0.11)	$	(0.06)	$	(0.17)	$	(0.10)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Options to purchase common stock		2,641		2,137		2,641		2,137
Warrants to purchase common stock		1,383		1,749		1,383		1,749

Derivative Instruments (Tables)

6 Months Ended

Jun. 30, 2017

Derivative Instruments [Abstract]

Unrealized Gain on Derivatives

	Three Months Ended June 30,				Six Months Ended June 30,
Gain/(Loss) on Derivative Instruments	2017		2016		2017		2016
Derivatives expired March 29, 2016		-		-		-		41
Options to contractors		(120)		(17)		(157)		(15)
Gain/(loss) on Derivative Instruments		(120)		(17)		(157)		26

Schedule of Other Share-based Compensation, Activity

The table below summarizes Canadian dollar denominated contractor option activity, since their issuance:

Contractor Options in $CAD	Three Month Period		Six-Month Period		Weighted-Average
Options in Thousands	Ending June 30, 2017				Exercise Price
Opening balance		40		40	$	1.81
Exercised		(1)		(1)	$	1.89
Forfeited		-		-	$	-
Expired		-		-	$	-
Ending balance		39		39	$	1.80

Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2017

Stockholders' Equity [Abstract]

Warrants Outstanding to Purchase Common Stock

Warrant	Common Shares Issuable Upon Exercise of		Exercise Price
Description	Outstanding Warrants at June 30, 2017		$USD			Expiration Date
Investor warrants		1,333	$	1.50	USD	November 22, 2018
Investor warrants		50	$	3.00	USD	February 2, 2019
Total		1,383

Schedule of Share Based Compensation, Stock Options Expense Recognized

The table below outlines recognized contractor and employee expense for the three and six-month periods ended June 30, 2017 and 2016.

	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Contractor options expense recognized		286		17		342		30
Employee options expense recognized		461		111		502		111
Total option expense recognized		747		128		844		141

Schedule of Share-based Compensation, Stock Options, Activity

The following is a summary of option activity for the three and six months ended June 30, 2017 for stock options denominated in US dollars:

	Number of		Weighted-Average
US Denominated Options	Options (thousands)		Exercise Price $USD
Outstanding December 31, 2016		1,428		1.93
Granted		-		-
Exercised		-		-
Forfeited		-		-
Outstanding at March 31, 2017		1,428		1.93
Granted		300		4.84
Exercised		(50)		0.64
Forfeited		-		-
Outstanding at June 30, 2017		1,678		2.48

The following is a summary of option activity for the three and six months ended June 30, 2017 for stock options denominated in Canadian dollars:

	Number of		Weighted-Average
Canadian Denominated Options	Options (thousands)		Exercise Price $CAD
Outstanding December 31, 2016		999		2.38
Granted		-		-
Exercised		-		-
Forfeited		-		-
Outstanding at March 31, 2017		999		2.38
Granted		-		-
Exercised		(36)		2.42
Forfeited		-		-
Outstanding at June 30, 2017		963		2.37

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions

Assumptions for the valuation of the option grants are described in the table below:

	Three Months Ended June 30,
Black-Scholes Model Assumptions	2017			2016
Expected dividend		0.00	%		0.00	%
Risk free rate		2.04 – 2.16	%		1.51	%
Expected volatility		133 - 167	%		137	%
Expected life		7 years			7 years

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2017

Fair Value Disclosures [Abstract]

Assets/Liabilities Measured at Fair Value on Recurring Basis

Fair Value Measurement at June 30, 2017

Quoted Price in

Active Markets for

Significant

Assets/Liabilities Measured at

Identical

Significant Other

Unobservable

Fair Value on a Recurring Basis

Instruments

Observable Inputs

Inputs

Level 1

Level 2

Level 3

Total

Assets

Cash and cash equivalents

127

⁽¹⁾

10,105

10,232

Liabilities

Derivative liabilities

190

(1)

The Company held $127 in cash of which $67 (as presented in US dollars) was in Canadian funds.

Nature of Business and Going Concern - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Mar. 31, 2017	Dec. 31, 2016	Mar. 31, 2016	Dec. 31, 2015
Going Concern [Line Items]
Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total	$ (688)	$ (470)	$ (1,363)	$ (969)
Retained Earnings (Accumulated Deficit)	(116,726)		(116,726)			$ (114,322)
Operating Income (Loss)	(1,479)	(707)	(2,250)	(1,161)
Cash and Cash Equivalents, at Carrying Value, Total	$ 10,232	$ 5,081	$ 10,232	$ 5,081	$ 3,251	$ 3,926	$ 545	$ 942

Significant Accounting Policies - Additional Information (Details) $ in Thousands, $ in Thousands	Jun. 30, 2017 USD ($)	Jun. 30, 2017 CAD ($)	Dec. 31, 2016 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Money market investments	$ 10,232		$ 3,926
Cash	127	$ 67	$ 51
Money Market Funds [Member]
Summary Of Significant Accounting Policies [Line Items]
Money market investments	$ 10,105

Earnings per Share (Schedule of Earnings Per Share, Basic and Diluted) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2017	Mar. 31, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Numerator:
Net (loss)	$ (1,598)	$ (806)	$ (724)	$ (2,404)	$ (1,144)
Denominator:
Weighted-average common shares, basic	14,192		12,813	13,917	11,873
Incremental dilutive shares	0		0	0	0
Weighted-average common shares, diluted	14,192		12,813	13,917	11,873
Net (loss) per share, basic and diluted	$ (0.11)		$ (0.06)	$ (0.17)	$ (0.10)
Warrant [Member]
Denominator:
Dilutive effect of warrants	0		0	0	0
Employee Stock Option [Member]
Denominator:
Dilutive effect of warrants	0		0	0	0

Earnings per Share (warrants were excluded from the computation of basic and diluted net loss per share) (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,641	2,137	2,641	2,137
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,383	1,749	1,383	1,749

Derivative Instruments (fair value liability) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Gain/(Loss) on Derivative Instrument
Unrealized Gain (Loss) on Derivatives	$ (120)	$ (17)	$ (157)	$ 26
Options [Member]
Gain/(Loss) on Derivative Instrument
Unrealized Gain (Loss) on Derivatives	(120)	(17)	(157)	(15)
Derivative on March 29, 2016 [Member]
Gain/(Loss) on Derivative Instrument
Unrealized Gain (Loss) on Derivatives	$ 0	$ 0	$ 0	$ 41

Derivative Instruments (Contractor Option Activity) (Details) - $ / shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Mar. 31, 2017	Jun. 30, 2017
Stock Options Issuance Outstanding at Beginning	40	40	40
Stock Options Issuance Exercised	(1)		(1)
Stock Options Issuance Forfeited	0		0
Stock Options Issuance Expired	0		0
Stock Options Issuance Outstanding at Ending	39	40	39
Weighted-average Exercise Price Outstanding and Exercisable at Beginning		$ 1.81	$ 1.81
Weighted-average Exercise Price Exercised			1.89
Weighted-average Exercise Price Forfeited			0
Weighted-average Exercise Price Expired			0
Weighted-average Exercise Price Outstanding and Exercisable at Ending	$ 1.8		$ 1.8

Derivative Instruments - Additional Information (Details) $ / shares in Units, shares in Thousands, $ in Thousands, $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2017 CAD ($) $ / shares shares	Jun. 30, 2017 USD ($) shares	Jun. 30, 2017 CAD ($) $ / shares shares	Dec. 31, 2011 shares	Dec. 31, 2010 shares
Derivative [Line Items]
Common shares issuable upon exercise of outstanding warrants	1,383		1,383
Fair Value Assumptions, Expected Dividend Rate		0.00%	0.00%
Fair Value Assumptions, Risk Free Interest Rate		1.10%	1.10%
Stock Options Issuance Exercised	1	1	1
Proceeds from Stock Options Exercised		$ 66	$ 87
Minimum [Member]
Derivative [Line Items]
Fair Value Assumptions, Expected Volatility Rate		88.00%	88.00%
Fair Value Assumptions, Expected Term		6 months	6 months
Maximum [Member]
Derivative [Line Items]
Fair Value Assumptions, Expected Volatility Rate		98.00%	98.00%
Fair Value Assumptions, Expected Term		10 months 17 days	10 months 17 days
Invester Option [Member]
Derivative [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	39		39
Canadian Dollar [Member]
Derivative [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number				36	29
Proceeds from Stock Options Exercised	$ 1	$ 1	$ 1
Contractor Options Expire On November 19, 2017 [Member]
Derivative [Line Items]
Common shares issuable upon exercise of outstanding warrants	20		20
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 1.89		$ 1.89
Contractor Options Expire On April 4, 2018 [Member]
Derivative [Line Items]
Common shares issuable upon exercise of outstanding warrants	17		17
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 1.62		$ 1.62
Contractor Options Expire On May 18, 2018 [Member]
Derivative [Line Items]
Common shares issuable upon exercise of outstanding warrants	2		2
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 2.43		$ 2.43

Shareholder rights plan - (Additional Information (Details)

6 Months Ended

Jun. 30, 2017

Shareholders Rights Plan Agreement Description

Stockholders' Equity (Warrants Outstanding to Purchase Common Stock) (Details) shares in Thousands	6 Months Ended
	Jun. 30, 2017 $ / shares shares
Class of Warrant or Right [Line Items]
Common shares issuable upon exercise of outstanding warrants	1,383
Inverstor warrants one
Class of Warrant or Right [Line Items]
Common shares issuable upon exercise of outstanding warrants	1,333
Exercise price in CAD/USD Dollars \| $ / shares	$ 1.50
Expiration Date	Nov. 22, 2018
Investor warrants two
Class of Warrant or Right [Line Items]
Common shares issuable upon exercise of outstanding warrants	50
Exercise price in CAD/USD Dollars \| $ / shares	$ 3.00
Expiration Date	Feb. 02, 2019

Stockholders' Equity (Recognized Contractor and Employee Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Recognized Employee Expense [Line Items]
Contractor options expense recognized	$ 286	$ 17	$ 342	$ 30
Employee options expense recognized	461	111	502	111
Total option expense recognized	$ 747	$ 128	$ 844	$ 141

Stockholders' Equity (Summary of Option Activity) (Details) shares in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2017 $ / shares shares	Jun. 30, 2017 $ / shares shares	Mar. 31, 2017 $ / shares shares	Mar. 31, 2017 $ / shares shares	Jun. 30, 2017 $ / shares shares	Jun. 30, 2017 $ / shares shares
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Number of Options Exercised \| shares					(36)	(36)
Weighted-average Exercise Price Exercised						$ 1.89
Weighted-average Exercise Price, Forfeited						$ 0
Stock Option In Canadian Dollars [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Number of Options Outstanding at Beginning \| shares	999	999	999	999	999	999
Number of Options Granted \| shares	0	0	0	0
Number of Options Exercised \| shares	(36)	(36)	0	0
Number of Options Forfeited \| shares	0	0	0	0
Number of Options Outstanding at Ending \| shares	963	963	999	999	963	963
Weighted-average Exercise Price outstanding at Beginning		$ 2.38		$ 2.38		$ 2.38
Weighted-average Exercise Price Granted		0		0
Weighted-average Exercise Price Exercised		2.42		0
Weighted-average Exercise Price, Forfeited		0		0
Weighted-average Exercise Price Outstanding at Ending		$ 2.37		$ 2.38		$ 2.37
Stock Option In Us Dollars [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Number of Options Outstanding at Beginning \| shares	1,428	1,428	1,428	1,428	1,428	1,428
Number of Options Granted \| shares	300	300	0	0
Number of Options Exercised \| shares	(50)	(50)	0	0
Number of Options Forfeited \| shares	0	0	0	0
Number of Options Outstanding at Ending \| shares	1,678	1,678	1,428	1,428	1,678	1,678
Weighted-average Exercise Price outstanding at Beginning	$ 1.93		$ 1.93		$ 1.93
Weighted-average Exercise Price Granted	4.84		0
Weighted-average Exercise Price Exercised	0.64		0
Weighted-average Exercise Price, Forfeited	0		0
Weighted-average Exercise Price Outstanding at Ending	$ 2.48		$ 1.93		$ 2.48

Stockholders' Equity(volatility of our stock based on the contractual life)(Details)	3 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Expected dividend	0.00%	0.00%
Risk-free interest rate		1.51%
Expected volatility		137.00%
Expected life	7 years	7 years
Maximum [Member]
Risk-free interest rate	2.16%
Expected volatility	167.00%
Minimum [Member]
Risk-free interest rate	2.04%
Expected volatility	133.00%

Stockholders' Equity - Additional Information (Details) $ / shares in Units, shares in Thousands, $ in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017 USD ($) $ / shares shares	Jun. 30, 2016 USD ($) shares	Jun. 30, 2017 USD ($) $ / shares shares	Jun. 30, 2017 CAD ($) shares	Jun. 30, 2016 USD ($)
Stockholders Equity Note [Line Items]
Shares issuable under Stock Option Plan, as percent of shares outstanding			25.00%	25.00%
Proceeds from Issuance of Private Placement \| $	$ 7,571	$ 5,000	$ 7,571		$ 5,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period			36	36
Proceeds from Stock Options Exercised			$ 66	$ 87
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	300	49
US Denominated [Member]
Stockholders Equity Note [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period	50
Proceeds from Stock Options Exercised \| $	$ 32
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	1,678		1,678
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	1,378		1,378
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	1,228		1,228
Derivative [Member]
Stockholders Equity Note [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period			1	1
Non-Derivative [Member]
Stockholders Equity Note [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period			35	35
Common Stock [Member]
Stockholders Equity Note [Line Items]
Stock Issued During Period, Shares, New Issues	1,900
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period	86
U.S.dollars [Member]
Stockholders Equity Note [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 1.55		$ 1.55
Class Or Warrant Or Right Outstanding Weighted Average Remaining Contractual Terms			1 year 7 months 24 days	1 year 7 months 24 days
Private Placement [Member] \| Common Stock [Member]
Stockholders Equity Note [Line Items]
Stock Issued During Period, Shares, New Issues	1,900
Proceeds from Issuance of Private Placement \| $	$ 7,600
Equity Issuance Per Share Amounts \| $ / shares	$ 4.00
Payments of Stock Issuance Costs \| $	$ 7,571
Maximum [Member]
Stockholders Equity Note [Line Items]
Shares issuable under Stock Option Plan	3,907		3,907

Fair Value Measurements (Assets/Liabilities Measured at Fair Value on Recurring Basis) (Details)
$ in Thousands

Jun. 30, 2017

USD ($)

Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]

Cash and cash equivalents

$ 10,232

Derivative liabilities

190

Quoted Price in Active Markets for Identical Instruments Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]

Cash and cash equivalents

127

^[1]

Derivative liabilities

Significant Other Observable Inputs Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]

Cash and cash equivalents

10,105

Derivative liabilities

Significant Unobservable Inputs Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]

Cash and cash equivalents

Derivative liabilities

$ 190

[1]	The Company held $127 in cash of which $67 (as presented in US dollars) was in Canadian funds.

Fair Value Measurements (Assets/Liabilities Measured at Fair Value on Recurring Basis) (Parenthetical) (Details) $ in Thousands, $ in Thousands	Jun. 30, 2017 USD ($)	Jun. 30, 2017 CAD ($)	Dec. 31, 2016 USD ($)
Assumptions used to Determine Fair Value Options [Line Items]
Cash	$ 127	$ 67	$ 51

Commitments and Contingencies - Additional information (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2017 USD ($)
Operating Leases, Rent Expense	$ 3
Rostislav Raykov
Severance Costs Payable In Case Of Termination Other Than For Cause	250
Robert Andrade [Member]
Severance Costs Payable In Case Of Termination Other Than For Cause	$ 95

Subsequent Events - Additional information (Details) - shares shares in Thousands	Aug. 11, 2017	Jun. 30, 2017
Class Of Warrant Or Right Outstanding		1,383
Subsequent Event [Member]
Number Of Common Shares , Registered	8,243